tumor
cell
chronic
lymphocyt
leukemia
accumul
peripheri
prolifer
minor
cell
lymph
node
prolif
surviv
signal
prolifer
center
includ
interact
lymphocyt
express
ligand
demonstr
low
toxic
combin
bezafibr
medroxyprogesteron
acet
induc
mitochondri
superoxidemedi
apoptosi
cell
cell
expos
ligand
assess
abil
dasatinib
lycorin
restor
bezafibrateand
medroxyprogesteron
acetateinduc
apoptosi
cell
expos
ligand
parallel
experi
compar
abil
dasatinib
induc
apoptosi
cell
cotreat
fludarabin
primari
chronic
lymphocyt
leukemia
peripher
blood
mononuclear
cell
expos
drug
combin
hour
control
ligandexpress
fibroblast
monolay
cell
harvest
analyz
apoptosi
level
mitochondri
superoxid
use
flow
cytometri
experi
cell
remov
ligand
hour
retreat
analyz
hour
effect
ligand
drug
treatment
mitochondri
superoxid
level
assess
previous
describ
dasatinib
render
cell
sensit
fludarabin
ligand
remov
last
hour
cultur
contrast
lycorin
restor
bezafibrateand
medroxyprogesteron
acetateinduc
apoptosi
associ
mitochondri
superoxid
even
continu
exposur
ligand
furthermor
combin
bezafibr
medroxyprogesteron
acet
lycorin
littl
effect
normal
peripher
blood
mononuclear
cell
wherea
dasatinib
fludarabin
induc
high
level
apoptosi
data
indic
potenti
bezafibr
medroxyprogesteron
acet
lycorin
novel
therapi
chronic
lymphocyt
leukemia
import
implic
report
potenti
cabl
kinas
inhibitor
diseas
abstract
haematologica
chronic
lymphocyt
leukemia
cll
diseas
neoplast
b
cell
character
progress
accumul
b
lymphocyt
peripher
blood
bone
marrow
secondari
lymphoid
organ
western
world
common
form
adult
leukemia
wide
variabl
clinic
cours
mani
patient
never
requir
therapi
new
case
per
year
worldwid
major
patient
year
old
accord
recent
surveil
epidemiolog
end
result
median
age
diagnosi
year
younger
patient
current
frontlin
therapi
combin
fludarabin
cyclophosphamid
rituximab
regimen
associ
signific
toxic
elderli
patient
cll
remain
incur
major
patient
becom
refractori
chemotherapi
need
develop
less
toxic
novel
therapi
overcom
drug
resist
tumor
microenviron
particular
lymph
node
shown
center
cll
cell
prolifer
protect
cell
chemotherapeut
lymph
node
rich
cell
express
ligand
engag
cll
cell
via
stimul
prolifer
prolifer
center
protect
apoptot
signal
histopatholog
confirm
within
prolifer
center
prolifer
cll
cell
directli
expos
signal
furthermor
cll
cell
protect
spontan
apoptosi
vitro
cocultur
autolog
cell
mani
studi
includ
demonstr
cll
cell
protect
druginduc
apoptosi
cultur
therapi
overcom
protect
mechan
within
prolifer
center
also
target
circul
neoplast
cell
like
provid
better
respons
rate
reduc
rate
relaps
encouragingli
hallaert
et
al
recent
found
protect
effect
could
overcom
use
cabl
kinas
inhibitor
dasatinib
report
due
reduct
antiapoptot
protein
propos
agent
could
success
sensit
cll
cell
within
lymph
node
chemotherapeut
fludarabin
howev
signal
provid
continu
apoptosi
associ
dasatinib
treatment
appar
follow
remov
therefor
categor
conclud
dasatinib
would
abl
overcom
vivo
sensit
cll
cell
therapeut
addit
question
whether
dose
fludarabin
clinic
achiev
sinc
report
peak
concentr
fludarabin
lymphocyt
plasma
investig
vitro
potenti
combin
bezafibr
medroxyprogesteron
acet
mpa
cll
acut
myeloid
leukemia
burkitt
lymphoma
also
conduct
phase
ii
clinic
studi
combin
bezafibr
mpa
acut
myeloid
leukemia
phase
ii
studi
show
combin
clinic
benefit
associ
hematolog
system
toxic
find
indic
potenti
benefit
exploit
therapi
cll
patient
especi
frail
abl
endur
toxic
regimen
howev
although
demonstr
bezafibr
mpa
could
induc
apoptosi
cll
cell
reduc
prolifer
observ
combin
bezafibr
mpa
provok
apoptosi
cell
lack
apoptosi
presenc
associ
protect
bezafibr
mpainduc
mitochondri
superoxid
product
studi
examin
whether
addit
third
agent
could
overcom
protect
signal
provid
lead
restor
mitochondri
superoxid
accumul
success
apoptosi
cll
cell
within
environ
mankind
alway
use
plant
sourc
natur
medicin
inde
extract
narcissu
genu
amaryllidacea
document
use
cancer
therapi
hippocr
th
centuri
bc
recent
decad
scientif
commun
investig
therapeut
use
numer
plantderiv
compound
mani
studi
antileukemia
therapi
includ
deriv
euphorbia
peplu
treatment
acut
myeloid
leukemia
jasmon
plant
hormon
found
plant
acut
myeloid
leukemia
cll
bcell
lymphoma
pancratistatin
lycorin
amaryllidacea
famili
acut
myeloid
leukemia
acut
promyelocyt
leukemia
lycorin
abund
amaryllidacea
alkaloid
wide
rang
biolog
activ
studi
centuri
indic
lycorin
interfer
replic
polio
small
pox
sar
virus
antifung
activ
antiparasit
includ
malaria
last
decad
research
focus
potenti
use
compound
treat
cell
resist
apoptot
stimuli
includ
leukem
cell
vitro
studi
set
shown
lycorin
induc
apoptosi
specif
target
malign
cell
potenti
use
therapeut
agent
recent
led
studi
product
synthet
compound
highlight
potenti
lead
drug
develop
studi
investig
potenti
combin
lycorin
bezafibr
mpa
elicit
apoptot
respons
presenc
assess
correl
induc
apoptosi
gener
mitochondri
superoxid
compar
find
hallaert
et
al
look
import
continu
provis
truli
mimic
lymph
node
environ
cll
cell
use
unselect
patient
diagnos
bcell
cll
accord
standard
morpholog
immunophenotyp
clinic
criteria
attend
outpati
clinic
birmingham
heartland
hospit
uk
patient
provid
inform
written
consent
studi
receiv
local
ethic
approv
normal
donor
recruit
follow
inform
consent
primari
mononuclear
cell
prepar
use
ficol
paqueplu
anachem
previous
describ
cell
cultur
use
l
cell
murin
l
cell
stabli
transfect
plasmid
encod
describ
previous
well
nontransfect
l
cell
gift
prof
john
gordon
maintain
treat
mitomyocin
c
sigma
seed
cocultur
describ
previous
mononuclear
cell
seed
stromal
l
cell
ratio
rpmi
fetal
bovin
serum
penicillinstreptomycin
ngml
r
system
treat
describ
text
cll
cell
remov
stroma
describ
previous
cll
cell
either
analyz
immedi
follow
remov
wash
warm
phosphatebuff
salin
resuspend
rpmi
supplement
ngml
appropri
treatment
cultur
h
analysi
immedi
prior
harvest
cultur
view
use
invert
microscop
ensur
integr
stromal
support
follow
treatment
stock
x
bezafibr
dimethylsulfoxid
mm
mpa
ethanol
mm
fludarabin
x
stock
mm
lycorin
sigma
pool
uk
dimethylsulfoxid
mm
dasatinib
lc
laboratori
usa
dimethylsulfoxid
store
treatment
set
triplic
control
contain
highest
concentr
carrier
solvent
use
correspond
treatment
analys
carri
flow
cytometri
bd
fac
calibur
util
cell
quest
pro
softwar
bd
follow
treatment
cll
cell
triplic
well
pool
incub
annexin
v
propidium
iodid
annexin
v
fitc
kit
bd
oxford
uk
accord
manufactur
instruct
mitosox
red
molecular
probe
use
assess
presenc
mitochondri
superoxid
pool
triplic
well
describ
previous
cll
cell
cultur
plate
stroma
stroma
treat
h
h
respect
cell
remov
stromal
support
describ
wash
phosphatebuff
salin
pellet
snapfrozen
liquid
nitrogen
whole
cell
pellet
lyse
laemmli
dye
load
buffer
boil
min
cll
lysat
togeth
lysat
huh
cell
use
posit
control
separ
sodiumdodecylsulf
polyacrylamid
gel
electrophoresi
prior
semidri
transfer
polyvinyliden
fluorid
immobilonp
membran
millipor
corp
watford
hert
uk
membran
block
h
wv
nonfat
milk
powder
marvel
wisbech
camb
uk
trisbuff
salin
tbst
briefli
wash
probe
dilut
antisodii
antibodi
bd
wv
nonfat
milk
powder
trisbuff
salin
overnight
follow
wash
tbst
membran
probe
antimous
antibodi
sigma
dilut
min
signal
develop
use
supersign
west
pico
chemiluminesc
substrat
pierc
cramlington
northumberland
uk
autorad
expos
min
equal
load
assess
use
antibodi
sigma
dilut
min
antimous
secondari
antibodi
dilut
min
develop
data
report
mean
valu
standard
deviat
standard
error
mean
state
p
valu
calcul
use
nonparametr
wilcoxon
test
spss
version
use
fludarabin
dose
close
reflect
achiev
plasma
intralymphocyt
concentr
abl
reproduc
observ
report
hallaert
et
al
dasatinib
induc
apoptosi
alon
combin
dasatinib
fludarabin
follow
continu
drug
exposur
h
final
h
treatment
absenc
figur
howev
use
methodolog
bezafibr
mpa
also
induc
apoptosi
similar
level
dasatinib
fludarabin
contrast
describ
previous
therefor
induc
cll
cell
apoptosi
follow
releas
protect
also
seen
bezafibr
mpa
data
indic
dasatinib
fludarabin
combin
repres
advantag
bezafibr
mpa
indic
dasatinib
overcom
previous
suggest
protect
cll
cell
fludarabin
hypothes
addit
appropri
third
agent
may
abl
overcom
protect
effect
bezafibr
mpa
result
desir
induct
apoptosi
follow
recent
public
use
lycorin
caus
apoptosi
acut
promyelocyt
leukemia
acut
myeloid
leukemia
cell
line
investig
whether
agent
potenti
cll
dose
titrat
lycorin
start
highest
dose
shown
effect
cell
lui
et
al
conduct
cll
sampl
six
patient
presenc
none
dose
test
induc
signific
apoptosi
primari
cll
cell
treatment
figur
howev
addit
lycorin
bezafibr
mpa
prove
effect
induc
death
cll
cell
even
continu
expos
figur
b
even
lowest
dose
test
combin
bezafibr
mpa
potenti
apoptosi
compar
cell
treat
bezafibr
mpa
alon
proapoptot
effect
bezafibr
mpa
lycorin
reach
plateau
dose
lycorin
signific
increas
level
apoptosi
higher
dose
test
previou
studi
show
bezafibr
mpainduc
apoptosi
absenc
associatlyocrin
sensit
cll
cell
haematologica
ed
product
reactiv
oxygen
speci
mitochondri
superoxid
contrast
surviv
bezafibr
mpatreat
cell
presenc
associ
induct
reactiv
oxygen
speci
mitochondri
superoxid
argu
protect
bezafibr
mpainduc
apoptosi
protect
counter
mitochondri
superoxid
product
test
whether
capac
lycorin
potenti
abil
bezafibr
mpa
induc
apoptosi
cell
expos
associ
restor
mitochondri
superoxid
respons
h
consist
lack
cell
death
induc
lycorin
alon
agent
induc
mitochondri
superoxid
product
figur
b
small
increas
mitochondri
superoxid
observ
respons
lycorin
howev
even
dose
amount
mitochondri
superoxid
produc
produc
bezafibr
mpa
alon
figur
b
contrast
combin
bezafibr
mpa
lycorin
induc
substanti
lycorinedosedepend
increas
mitochondri
superoxid
bezafibr
mpa
lycorin
produc
highest
level
mitochondri
superoxid
figur
importantli
lycorinemitochondri
superoxid
doserespons
mirror
induct
apoptosi
measur
annexin
v
stain
cell
viabil
figur
direct
comparison
total
mitochondri
superoxid
viabl
event
figur
annexin
v
stain
mitochondri
superoxid
figur
demonstr
increas
mitochondri
superoxid
hayden
et
al
haematologica
directli
associ
loss
viabil
apoptosi
data
two
measur
apoptosi
compar
mitochondri
superoxid
product
indic
apoptosi
caus
combin
bezafibr
mpa
lycorin
like
due
restor
accumul
mitochondri
superoxid
within
treat
cell
previou
studi
demonstr
transcript
mitochondri
superoxid
antioxid
manganes
superoxid
dismutas
upregul
cell
expos
tumor
necrosi
ligand
member
tumor
necrosi
factor
famili
hypothes
cll
cell
expos
may
also
upregul
manganes
superoxid
dismutas
therebi
overcom
proapoptot
effect
exert
bezafibr
mpa
altern
bezafibr
mpa
may
induc
apoptosi
absenc
downregul
manganes
superoxid
dismutas
action
may
counteract
accord
hypothesi
lycorin
presenc
would
revers
downregul
howev
western
blot
analysi
protein
express
reveal
upregul
manganes
superoxid
dismutas
figur
neither
absenc
presenc
bezafibr
mpa
lycorin
combin
abl
induc
downregul
protein
figur
next
investig
effect
lycorin
cll
cell
absenc
lycorin
alon
induc
modest
dosedepend
increas
apoptosi
figur
even
highest
dose
test
lycorin
better
induc
apoptosi
bezafibr
mpa
combin
bezafibr
mpa
lycorin
increas
amount
apoptosi
observ
howev
effect
less
strike
detect
presenc
lyocrin
sensit
cll
cell
haematologica
previou
studi
demonstr
bezafibr
mpa
minim
effect
normal
b
cell
indic
tumor
cell
select
test
effect
dasatinib
fludarabin
normal
peripher
blood
mononuclear
cell
apoptosi
compar
respons
bezafibr
mpa
without
lycorin
neither
bezafibr
mpa
lycorin
tripl
combin
significantli
increas
apoptosi
peripher
blood
mononuclear
cell
either
presenc
absenc
figur
combin
bezafibr
mpa
lycorin
induc
apoptosi
data
shown
howev
sinc
signific
anticl
activ
lycorin
bezafibr
mpa
observ
dose
lycorin
suggest
dose
would
use
cll
therapi
dasatinib
induc
small
amount
peripher
blood
mononuclear
cell
apoptosi
figur
contrast
fludarabin
increas
apoptosi
peripher
blood
mononuclear
cell
cultur
without
furthermor
trend
significantli
increas
apoptosi
combin
dasatinib
fludarabin
compar
control
figur
despit
mani
develop
treatment
cll
improv
respons
rate
diseas
remain
incur
overcom
chemoresist
without
high
level
toxic
prioriti
migrat
circul
cll
cell
lymph
node
provid
cell
surviv
signal
caus
develop
prosurviv
nich
wide
believ
sourc
therapi
resist
relaps
chemoresist
report
cll
cell
expos
vogler
et
al
recent
demonstr
cll
cell
expos
increas
resist
novel
therapeut
appear
therefor
protect
cll
cell
varieti
potenti
treatment
thu
could
specul
cll
cell
effect
seek
cover
antineoplast
therapi
exploit
within
lymph
node
recent
shown
bezafibr
mpa
induc
apoptosi
circul
cll
cell
significantli
reduc
prolif
capabl
cll
cell
engag
howev
lack
apoptosi
within
environ
mimick
lymph
node
led
search
third
agent
combin
bezafibr
mpa
aim
exert
apoptosi
absenc
presenc
recent
studi
hallaert
et
al
identifi
possibl
use
dasatinib
agent
sensit
cll
cell
therapi
furthermor
scenario
action
combin
dasatinib
fludarabin
greater
bezafibr
mpa
howev
lycorin
abl
sensit
cll
cell
bezafibr
mpainduc
apoptosi
continu
presenc
furthermor
abil
associ
restor
accumul
mitochondri
superoxid
respons
bezafibr
mpa
would
indic
either
lycorin
reinstat
capac
bezafibr
mpa
induc
mitochondri
superoxid
cell
interfer
clearanc
mitochondri
superoxid
first
studi
show
correl
gener
mitochondri
superoxid
cell
death
cll
postul
possibl
mechan
action
lycorin
andor
bezafibr
mpa
could
disrupt
regul
mitochondri
superoxid
manganes
superoxid
dismutas
howev
found
induc
upreglaut
superoxid
dismutas
agent
studi
interf
pathway
nonetheless
possibl
lycorin
exert
effect
via
mitochondri
mechan
support
studi
saccharomyc
cerevisia
demonstr
cell
lack
mitochondri
dna
resist
lycorin
elderli
cll
patient
commonli
exclud
clinic
trial
suscept
develop
cytopenia
infect
younger
patient
inevit
develop
chemoresist
convent
agent
thu
target
therapi
urgent
requir
studi
mononuclear
cell
isol
normal
donor
demonstr
combin
dasatinib
fludarabin
caus
signific
apoptosi
wherea
combin
bezafibr
mpa
lycorin
left
normal
cell
rel
unaffect
highlight
potenti
approach
current
mani
plant
compound
investig
intent
gain
fda
approv
therapeut
use
recent
prescript
drug
reminyl
approv
treatment
alzheim
diseas
activ
ingredi
compound
alkaloid
galanthamin
isol
anoth
member
amaryllidacea
famili
therefor
preced
set
use
group
agent
treatment
diseas
lycorin
identifi
novel
lead
anticanc
drug
design
jone
et
al
publish
first
success
studi
synthesi
framework
one
lycorin
sister
compound
thu
concept
lycorin
ultim
synthes
success
gain
fda
approv
therapeut
use
real
possibl
nonetheless
time
scale
cost
develop
new
drug
limit
addit
vivo
toxic
lycorin
yet
unknown
determin
prior
possibl
trial
combin
bezafibr
mpa
conclus
studi
continu
indic
bezafibr
mpa
potenti
therapi
cll
importantli
studi
provid
proof
principl
strategi
use
bezafibr
mpa
develop
potenti
target
cell
peripheri
protect
lymph
node
environ
demonstr
gener
mitochondri
superoxid
critic
apoptosi
remain
possibl
alreadi
avail
drug
could
also
target
cell
within
lymph
node
effect
lycorin
unfortun
appear
includ
dasatinib
screen
agent
could
yield
promis
result
data
would
suggest
agent
target
mitochondria
may
strong
candid
therefor
propos
ration
drug
screen
third
agent
base
gener
mitochondri
superoxid
measur
mitosox
suitabl
agent
could
found
would
expedi
way
develop
regim
clinic
viabl
treatment
inform
provid
author
contribut
person
list
author
acknowledg
avail
full
text
paper
wwwhaematologicaorg
financi
disclosur
provid
author
use
icmj
wwwicmjeorg
uniform
format
disclosur
compet
interest
also
avail
wwwhaematologicaorg
lyocrin
sensit
cll
cell
haematologica
